The Fertility Show, Manchester Central, 24-25 March 2018
Page URL:

Stroke patients improve after stem cell therapy

18 August 2014
Appeared in BioNews 767

Five stroke patients have begun to recover after being treated with their own stem cells, and have reported no side effects six months after treatment.

The patients were enrolled in a pilot study designed to test whether that therapy is safe.

'The improvements we saw in these patients are very encouraging, but it's too early to draw definitive conclusions about the effectiveness of the therapy', said Dr Soma Banerjee, a consultant at Imperial College Healthcare NHS Trust and one of the lead authors.

'We need to do more tests to work out the best dose and timescale for treatment before starting larger trials', Dr Banerjee added. At this stage, it cannot be excluded that the improvements in the treated patients occurred due to natural recovery after stroke.

Ischaemic stroke, affecting patients in this pilot study, occurs when blood supply to a certain part of the brain becomes limited due to the narrowing of blood vessels or a blood clot. It can take the form of either a total or partial anterior circulation stroke (TACS or PACS). TACS is the more severe variation; only four percent of patients experiencing TACS are expected to still be alive and independent six months after the stroke.

Of the treated patients, four suffered a TACS, resulting in loss of speech and paralysis of one side of the body. Among these, three were able to walk and look after themselves independently six months later. In addition, brain scans of all five patients showed that the size of brain damage decreased by an average of 28 percent over the six-month period. Importantly, no side effects from the stem cell therapy were observed and there were no signs of changes to the structure of blood vessels.

The stem cells, known as CD34+ cells, were collected from patients' bone marrow. They were then injected into an artery supplying the affected part of the brain, so that they could reach the site of the stroke. In previous studies on animals, these cells have been shown to release chemicals that promote growth of brain tissue and blood vessels.

The long-term goal of this research is to develop a drug mimicking the chemicals released by the CD34+ cells. 'Our aim is to develop a drug, based on the factors [chemicals] secreted by stem cells, that could be stored in the hospital pharmacy so that it is administered to the patient immediately following the diagnosis of stroke in the emergency room', said Professor Nagy Habib from Imperial College London.

This study was the first to specifically use CD34+ stem cells, and to administer them so early after the stroke. The findings were published in Stem Cells Translational Medicine.

Intra-Arterial Immunoselected CD34+ Stem Cells for Acute Ischemic Stroke
Stem Cells Translational Medicine |  8 August 2014
'Safe' stem cell therapy may help stroke recovery
NHS Choices |  11 August 2014
Stem cells show promise for stroke in pilot study
Imperial College London (press release) |  8 August 2014
'Stem cells show promise in stroke recovery'
BBC News |  9 August 2014
Stroke patients show promising signs of recovery after stem cell therapy
The Guardian |  8 August 2014
8 December 2014 - by Sean Byrne 
A gene variant has been linked to a lower risk of the most common cause of stroke in people under 50...
19 August 2013 - by Dr Lux Fatimathas 
Claims for the health benefits of the typically Mediterranean diet high in olive oil, fish, and complex carbohydrates are common, if hard to substantiate...
3 June 2013 - by Dr James Heather 
Five stroke patients in a stem cell therapy trial have shown improvements in their symptoms, according to interim results...
18 June 2012 - by Antony Blackburn-Starza 
Stroke patients involved in an early stage clinical trial of a stem cell treatment in Scotland have shown signs of slight improvement....
5 September 2011 - by Alison Cranage 
A pioneering clinical trial to inject stem cells into the brains of disabled stroke patients has been cleared to progress to the next stage after no safety concerns were raised in the first three patients....
Log in to add a Comment.

By posting a comment you agree to abide by the BioNews terms and conditions

Syndicate this story - click here to enquire about using this story.